Macrocure's CureXcell Phase III Leg Ulcer Study Futile
This article was originally published in Scrip
Israeli stem cell company Macrocure's lead wound-healing product CureXcell has stumbled in a US Phase III study in venous leg ulcers (VLU) – with a futility analysis revealing that it is not expected to meet its primary endpoint. Shares in the firm dropped by 72% to £3.33 in early trading on Nasdaq on Aug. 20, from a previous day's close of $12.05.
You may also be interested in...
Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.